Biosimilar activity in the EU on the decline, says analyst

14 September 2021

The European Union has been at the forefront in approving and accepting biosimilar copies of biological drugs, unlike the USA where there are still very few available on the market.

However, data and analytics company GlobalData now predicts that the arrival of biosimilar therapies in the EU will continue to fall in the coming years following a wave pattern that has been occurring since 2006.

Quentin Horgan, senior drugs database analyst at GlobalData, notes that we are currently in the downward trajectory of a wave that peaked in 2018, and it is likely that there are similar waves happening in the USA and APAC markets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK